Novo Nordisk Shares Plunge as 2026 Forecast Signals First Sales Slump in a Decade
Facing mounting pressure from rivals and U.S. pricing policies, Novo Nordisk warns of its first annual sales decline since 2017, sending its stock tumbling and forcing a strategic overhaul.